Vitamin C for Pre-Cancer Blood Disorders: Expert Trial Reaction

EVITA Trial Findings on Oral Vitamin C for Pre-Cancer Blood Disorders

The international, double-blind, randomized, placebo-controlled trial evaluated 1,000 mg daily oral vitamin C versus a placebo in 109 participants. According to the study, patients diagnosed with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies often exhibit chronically low levels of vitamin C. Led by the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team and University of Copenhagen professor Dr. Kirsten Grønbæk, the trial investigated whether restoring these nutrient levels could alter disease progression.

Researchers reported that the primary endpoint was not met. Dr. John Riches, a clinical reader in cancer immuno-metabolism at Barts Cancer Institute, noted that vitamin C failed to significantly slow the growth of abnormal blood-cell clones. However, participants taking the daily supplement experienced fewer adverse events during the trial and follow-up period.

Inflammatory Pathways and Exploratory Survival Data

Although cell growth rates remained comparable between the two groups, investigators discovered that vitamin C altered levels of inflammatory signaling molecules known as cytokines. These shifts suggest that the supplement may help regulate inflammatory pathways previously linked to the progression of pre-cancerous blood cells.

Furthermore, an exploratory survival analysis revealed a notable difference in overall outcomes. Participants who received the daily vitamin C regimen were significantly more likely to be alive after approximately three years of follow-up compared to those in the placebo group. Dr. Peter A. Jones, a distinguished professor at the Van Andel Institute and co-corresponding author, stated that the team is cautiously optimistic about the potential for cancer interception before the disease becomes established.

Next Steps for Phase 3 Clinical Research

Medical experts emphasize that the survival benefit was an unexpected finding from a relatively small study that was not initially designed to test whether vitamin C extends lifespan. Dr. Riches stated that while the results justify a larger investigation, current evidence remains insufficient to alter clinical practice or confirm that vitamin C improves long-term outcomes in early-stage blood cancers.

The research team intends to build upon these preliminary insights by examining the exact mechanisms by which vitamin C interacts with pre-cancer cells, including its potential role in restoring normal epigenetic function. Confirming the survival advantage will require a larger phase 3 clinical trial, and study leaders caution that it is currently too premature to establish definitive clinical recommendations.

Frequently Asked Questions

What was the dosage used in the EVITA clinical trial?

Participants in the treatment group took a daily dose of 1,000 mg of oral vitamin C for one year, while the control group received an identical-looking placebo.

Did vitamin C successfully stop the progression to leukemia?

No, the study found no significant difference between the vitamin C and placebo groups regarding the growth rates of abnormal blood cells.

Are there approved therapies to prevent CCUS progression?

Currently, there are no approved therapies that prevent CCUS progression into leukemia, though stem cell transplantation is utilized for certain conditions like myelodysplastic syndrome when patient health permits.